Prostate cancer treatment evolves through theranostics and robotic surgery

Advancements in prostate cancer management are increasingly utilizing theranostic approaches, where a single molecular target is used for both disease staging and treatment. A key target is the Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed on the surface of many prostate cancer cells, particularly in aggressive forms.

Diagnostic tools such as PSMA PET-CT scans allow medical teams to identify lesions that may be difficult to detect through conventional imaging. These results help multidisciplinary tumor boards determine if a patient is eligible for targeted therapies, such as lutetium-177 PSMA therapy, which is specifically indicated for patients with metastatic, progressive, and castration-resistant prostate cancer.

In clinical practice, early detection through routine PSA monitoring remains vital. In one documented case at SANADOR Clinical Hospital, a patient with rising PSA levels and no initial symptoms was diagnosed via MRI and fusion biopsy. The patient underwent a curative robotic radical prostatectomy using the da Vinci Xi system, successfully treating an acinar prostatic adenocarcinoma.